PKM2 Isoform-Specific Deletion Reveals a Differential Requirement for Pyruvate Kinase in Tumor Cells  by Israelsen, William J. et al.
PKM2 Isoform-Specific Deletion Reveals
a Differential Requirement for Pyruvate
Kinase in Tumor Cells
William J. Israelsen,1 Talya L. Dayton,1 Shawn M. Davidson,1 Brian P. Fiske,1 Aaron M. Hosios,1 Gary Bellinger,1 Jie Li,2
Yimin Yu,1 Mika Sasaki,3 James W. Horner,4,13 Laura N. Burga,3 Jianxin Xie,5 Michael J. Jurczak,6 Ronald A. DePinho,4,14
Clary B. Clish,7 Tyler Jacks,1 Richard G. Kibbey,6,8 Gerburg M. Wulf,3 Dolores Di Vizio,9,10,11 Gordon B. Mills,2
Lewis C. Cantley,3,12 and Matthew G. Vander Heiden1,4,*
1Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology, Cambridge, MA 02139, USA
2Department of Systems Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
3Department of Medicine, Division of Signal Transduction, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
5Cell Signaling Technology, Danvers, MA 01923, USA
6Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
7Metabolite Profiling Platform, Broad Institute, Cambridge, MA 02142, USA
8Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06510, USA
9Division of Cancer Biology and Therapeutics, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
10The Urological Diseases Research Center, Boston Children’s Hospital, Boston, MA 02115, USA
11Department of Surgery, Harvard Medical School, Boston, MA 02115, USA
12Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA
13Present address: Institute for Applied Cancer Science and the Department of Genomic Medicine, University of Texas M.D. Anderson
Cancer Center, Houston, TX 77030, USA
14Present address: Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
*Correspondence: mvh@mit.edu
http://dx.doi.org/10.1016/j.cell.2013.09.025SUMMARY
The pyruvate kinase M2 isoform (PKM2) is ex-
pressed in cancer and plays a role in regulating
anabolic metabolism. To determine whether PKM2
is required for tumor formation or growth, we gener-
ated mice with a conditional allele that abolishes
PKM2 expression without disrupting PKM1 expres-
sion. PKM2 deletion accelerated mammary tumor
formation in a Brca1-loss-driven model of breast
cancer. PKM2 null tumors displayed heterogeneous
PKM1 expression, with PKM1 found in nonprolifer-
ating tumor cells and no detectable pyruvate kinase
expression in proliferating cells. This suggests that
PKM2 is not necessary for tumor cell proliferation
and implies that the inactive state of PKM2 is
associated with the proliferating cell population
within tumors, whereas nonproliferating tumor cells
require active pyruvate kinase. Consistent with
these findings, variable PKM2 expression and het-
erozygous PKM2 mutations are found in human
tumors. These data suggest that regulation of
PKM2 activity supports the different metabolic
requirements of proliferating and nonproliferating
tumor cells.INTRODUCTION
Alterations in cell metabolism are a characteristic of many
cancers (Cairns et al., 2011), and the metabolic program of
rapidly proliferating cancer cells supports the biomass produc-
tion needed to produce daughter cells (Vander Heiden et al.,
2009). TheM2 isoform of pyruvate kinase (PKM2) is preferentially
expressed in cancer, where complex regulation of its activity is
important for control of cell metabolism (Chaneton and Gottlieb,
2012; Mazurek, 2011). Although most studies addressing the
role of PKM2 in cancer metabolism have relied on analysis of
cultured cells, cell culture does not recapitulate the metabolic
tumor microenvironment (Vaupel et al., 1989) or the tumor cell
heterogeneity that exists in vivo (Salk et al., 2010). Knockdown
of PKM2 in xenograft tumors has yielded contradictory results
regarding the requirement for PKM2 in tumor growth (Corte´s-
Cros et al., 2013; Goldberg and Sharp, 2012), further highlighting
the need to investigate the role of PKM2 in the context of spon-
taneous tumors arising in situ.
Pyruvate kinase catalyzes the final step in glycolysis by
transferring the phosphate from phosphoenolpyruvate (PEP)
to ADP, thereby generating pyruvate and ATP. In mammals,
pyruvate kinase is encoded by two genes that can each pro-
duce two isoforms. Tissue-specific promoters drive expression
of the PKL or PKR isoforms from the PKLR gene. PKR ex-
pression is exclusive to red blood cells, whereas PKL is ex-
pressed primarily in the liver, with low expression in the kidneyCell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 397
(Imamura and Tanaka, 1972; Mazurek, 2011). All other tissues
studied express a product of the PKM gene, which generates
either the PKM1 or PKM2 isoforms by including one of two
mutually exclusive exons during mRNA splicing (Noguchi et al.,
1986). The regulation of PKM splicing is dependent on multiple
splicing factors that bind within the PKM1 and PKM2 exons to
promote or suppress their inclusion in the mature transcript
(Clower et al., 2010; David et al., 2010; Wang et al., 2012).
PKM1 expression is found predominantly in differentiated adult
tissues with high ATP requirements, such as the heart, brain,
and muscle. PKM2 is expressed during development and in
many adult tissues, including the spleen, lung, and all cancers
and cancer cell lines studied to date (Clower et al., 2010; Ima-
mura and Tanaka, 1972; Mazurek, 2011).
PKM1 and PKM2 differ by 22 amino acids and have distinct
regulatory properties (Mazurek, 2011). Whereas PKM1 forms a
stable, constitutively active tetramer, PKM2 activity is controlled
by numerous allosteric effectors and posttranslational modifica-
tions that affect its tetramer stability. Binding of fructose-1,6-
bisphosphate (FBP), an upstream intermediate in glycolysis,
causes PKM2 to adopt a stable, active conformation similar to
that of PKM1 (Anastasiou et al., 2012; Christofk et al., 2008b).
PKM2 activation by FBP can be overridden by interaction of
PKM2 with tyrosine-phosphorylated proteins produced in
response to growth factor signaling (Christofk et al., 2008b; Var-
ghese et al., 2010). PKM2 activity is reduced by other posttrans-
lational modifications (Anastasiou et al., 2011; Lv et al., 2011),
and metabolites other than FBP can promote PKM2 activation
(Chaneton et al., 2012; Keller et al., 2012). These events illustrate
the complex regulation of PKM2 activity, and although PKM2
can exist in active or inactive states as a glycolytic enzyme, the
physiological significance of these states in cells or tumors is
not well understood.
It is reported that PKM2 is upregulated in cancer cells and
that PKM2 is the isoform expressed in all tumors. This suggests
that PKM2 expression provides a selective advantage over other
pyruvate kinase isoforms. Selection for PKM2 over PKM1 during
xenograft tumor growth has been observed (Christofk et al.,
2008a), and downregulation of PKM2 enzymatic activity by
phosphotyrosine growth signaling (Christofk et al., 2008a; Hito-
sugi et al., 2009; Varghese et al., 2010), cellular redox state
(Anastasiou et al., 2011), and lysine acetylation (Lv et al., 2011)
has been associated with tumor growth and anabolic meta-
bolism. Conversely, high pyruvate kinase activity due to exoge-
nous PKM1 expression or pharmacological activation of PKM2
can impair tumor growth and decrease levels of metabolites
critical for biosynthesis in vivo (Anastasiou et al., 2012). Taken
together, these studies support a model in which the ability of
PKM2 to be inactivated is important for cancer cell proliferation.
However, this model creates a quandary: if low pyruvate kinase
activity is favored by proliferating cancer cells, why is there
selection for PKM2 expression in cancer and not inactivation
of pyruvate kinase by gene mutation, deletion, or epigenetic
silencing?
One possibility is that the enzymatically inactive, nontetramer
form of pyruvate kinase has an important function in cancer
outside of glycolysis. Multiple nonmetabolic functions unique
to PKM2 have been proposed to play a vital role in cancer cell398 Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc.proliferation and tumor growth (Gao et al., 2012; Luo et al.,
2011; Yang et al., 2011, 2012a, and 2012b). In all cases, these
nonmetabolic functions are found only with PKM2 and not with
PKM1, suggesting that one or all may be driving PKM2 selection
in cancer. However, it remains unknown which, if any, are the
critical functions promoting PKM2 expression in tumors.
Another possibility is that PKM2 is selected because it can
exist in states of low or high enzymatic activity to allow for meta-
bolic adaptation to different physiological situations. Although
reduced PKM2 activity is associated with cell proliferation, it is
possible that enzyme reactivation is important for nonproliferat-
ing cancer cells that constitute a sizable fraction of tumor cells
in vivo. If this hypothesis is correct, there must be a subpopula-
tion of tumor cells in which high pyruvate kinase activity is
required. Studies of PKM2 in cancer to date have relied on
exogenous protein overexpression or RNA interference of
PKM2 expression in cell culture or xenograft tumor models
(Anastasiou et al., 2011; Christofk et al., 2008a; Corte´s-Cros
et al., 2013; Goldberg and Sharp, 2012; Luo et al., 2011; Yang
et al., 2011, 2012a, and 2012b). Although these methods
modulate PKM2 expression, they impair the endogenous, cell-
autonomous regulation of pyruvate kinase.
In this study, we report a conditional allele (Pkm2fl) that
allows Cre-recombinase-mediated deletion of the PKM2 iso-
form-specific exon. Excision of Pkm exon 10 selectively abro-
gates PKM2 protein production while still allowing PKM1 splicing
and protein expression. Loss of PKM2 in a mouse model of
breast cancer accelerates tumor formation. Mammary tumors
from Pkm2fl/fl mice show efficient deletion, suggesting that
PKM2 is not absolutely required for cell proliferation or tumor
growth. Only a subset of cells in Pkm2D/D tumors show compen-
satory PKM1 expression, and high PKM1 expression is anticor-
related with cell proliferation, supporting a model in which PKM2
expression in tumors facilitates low pyruvate kinase activity
needed for proliferation. Nonsense and missense mutations in
PKM2 occur in human tumors. These mutations include recur-
rent heterozygous stop mutations in PKM exon 10, consistent
with the idea that tumors tolerate or favor low pyruvate kinase
activity, lending further support to a model in which regulation
of PKM2 glycolytic activity is driving selection for this enzyme
isoform in tumors.
RESULTS
Generation and Characterization of a Conditional
PKM2 Allele
Pre-mRNA transcribed from the Pkm gene is spliced to produce
PKM1 or PKM2mRNA by inclusion of exon 9 or exon 10, respec-
tively (Figure 1A). To study the role of PKM2 in tumors in vivo,
we generated a mouse model that allows conditional deletion
of the PKM2-specific exon 10. LoxP sites flanking exon 10
were introduced into the Pkm locus of mouse embryonic stem
(ES) cells using homologous recombination (Figure 1A and Fig-
ure S1A available online). These ES cells were used to generate
chimeric mice, and mice generated from germline transmission
of the targeted allele were crossed with mice expressing FLP
recombinase to delete the neomycin resistance gene (Neor).
Breeding of these mice resulted in transmission of the PKM2
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Figure 1. Generation and Validation of PKM2 Conditional Mice
(A) The mouse Pkm locus, targeting construct, and resulting targeted, floxed, and deleted alleles. The KpnI sites used for Southern blot analysis are marked with
‘‘K,’’ and the new KpnI site introduced by the targeting vector is marked with ‘‘K*.’’ The locations of the 50 and 30 probes used for Southern blot analysis are also
shown.
(B) Southern blot analysis of KpnI-digested genomic DNA using a 50 probe. Digestion of the wild-type Pkm allele yields an8.3 kb fragment, and the floxed allele
yields a 6.0 kb fragment.
(C) PCR genotyping of genomic DNA from Pkm2+/+, Pkm2+/fl, and Pkm2fl/fl mice. Genotyping primers anneal outside of the loxP sites as indicated by arrows in (A)
and produce amplicons of 509 bp from the Pkm2+ allele and 577 bp from the Pkm2fl allele.
(D) PCR genotyping of Pkm2+/+ Cre-ER and Pkm2fl/fl Cre-ER MEFs that were treated with 4-hydroxytamoxifen (TAM) or were mock treated. The Pkm2D allele
produces a 195 bp amplicon.
(E) Western blot analysis of PKM2 protein from MEFs as specified in (D).
See also Figure S1.conditional allele (Pkm2fl) in Mendelian ratios. Pkm2fl/+ and
Pkm2fl/fl progeny were healthy and had no overt phenotype.
The presence of the Pkm2fl allele in adult mice was demon-
strated by Southern blot (Figures 1B, S1B, and S1C). To facilitate
husbandry and analysis, we developed a PCR-based strategy
for determination of Pkm2 genotypes (Figure 1C). We next
sought to verify that the Pkm2fl allele allows disruption of
PKM2 expression via Cre-mediated excision of Pkm exon 10.
Mice with Pkm2fl and inducible Cre recombinase (Cre-ER) alleles
were crossed to produce mouse embryonic fibroblasts (MEFs)
for analysis. Treatment of these MEFs with 4-hydroxytamoxifen
resulted in excision of Pkm exon 10 in Pkm2fl/fl cells (Figure 1D),and western blot analysis showed loss of PKM2 protein in the
Pkm2D/D MEFs (Figure 1E). These data confirm that the Pkm2fl
allele allows exon 10 deletion and disruption of PKM2 protein
production.
PKM2 Loss Accelerates Tumor Formation and Promotes
Liver Metastasis in a Mouse Model of Breast Cancer
To investigate the role of PKM2 in tumor formation, Pkm2
conditional mice were crossed to an established model of
breast cancer (Xu et al., 1999). In this model, loss of the Brca1
tumor suppressor in Brca1fl/fl MMTV-Cre Trp53+/ mice results
in mammary tumors by 1 year of age. The Pkm2fl allele shouldCell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 399
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Figure 2. Pkm Exon 10 Deletion in Mammary Tumors Results in Accelerated Mortality and Variable Production of PKM1 mRNA
(A) Kaplan-Meier survival curve comparing Pkm2+/+ and Pkm2fl/fl mice with Brca1fl/fl MMTV-Cre Trp53+/ alleles.
(B) PCR genotyping of the Pkm2 allele in Pkm2+/+ and Pkm2D/D mammary tumors. Analysis of tail DNA from Pkm2+/+ and Pkm2fl/fl mice is shown as a control.
(C) PKM2 mRNA levels in Pkm2+/+ and Pkm2D/D tumors by quantitative RT-PCR, with normal mouse tissue controls. M, muscle; H, heart; B, brain; K, kidney.
(D) PKM1 mRNA levels in Pkm2+/+ and Pkm2D/D tumors by quantitative RT-PCR, with normal mouse tissue controls. K, kidney; M, muscle; H, heart; B, brain.
(E) PKLR mRNA levels in Pkm2+/+ and Pkm2D/D tumors by quantitative RT-PCR, with normal mouse tissue controls. L, liver; K, kidney.
(F) Autoradiograph of uncut (U) and PstI (P) digested Pkm cDNA amplicons. Uncut PKM1 and PKM2 amplicons are of identical length (band 1). PstI digests only
the PKM2 amplicon to produce bands 2 and 3. Results from three representative Pkm2+/+ tumors are shown with quantification. See Figures S2C and S2E for a
schematic of how each band is generated.
(G) Autoradiograph of uncut (U) and digested PKM cDNA amplicons from a representative Pkm2D/D tumor. Uncut PKM1 and PKM2 amplicons are of identical
length (band 1), and the amplicon corresponding to the PKM-skip mis-spliced product is marked with an arrowhead (band 3). NcoI (N) digests the PKM1 am-
plicon, and PstI (P) digests the PKM2 amplicon. Figures S2C, S2D, and S2F show how each band is generated.
(H) Quantification of PKM splicing in Pkm2D/D tumors, as determined from autoradiographs as in (G).
Data are displayed as means ± SEM. n = 4. See also Figure S2.also undergo recombination in theCre-expressing epithelial cells
that give rise to tumors in this model. Because PKM2 has been
implicated as playing an important role in cancer, we expected
Pkm2 deletion to result in fewer tumors or delayed tumor onset.
Surprisingly, Pkm2fl/fl mice showed accelerated tumor-associ-
ated mortality when compared to their Pkm2+/+ counterparts
(Figure 2A).
We characterized tumors from Pkm2+/+ and Pkm2fl/fl mice
to investigate potential factors accounting for accelerated
mortality in Pkm2fl/fl mice. One possibility is that PKM2 loss
changes the balance of proliferation and apoptosis. Staining of400 Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc.tumor sections for the proliferative marker Ki-67 and for the
apoptosis marker cleaved caspase-3 did not reveal overt
differences between the genotypes (Figure S2A). However,
macroscopic metastases were observed in livers from three
out of five Pkm2fl/fl mice compared to none of seven PKM2+/+
mice evaluated for possible metastases (Figure S2B). To our
knowledge, metastasis to the liver has not been reported in
this mouse model of breast cancer.
To confirm that PKM2 is deleted in tumors from Pkm2fl/fl mice,
we examined the efficiency of Cre-mediated exon 10 deletion
by PCR. Qualitative deletion of Pkm exon 10 was observed in
all tumors derived from Pkm2fl/fl mice (Figure 2B), and quantita-
tive PCR (qPCR) analysis of tumor transcripts showed very low
levels of PKM2mRNAcompared towild-type tumors (Figure 2C).
Because Pkm2D/D tumor cells can potentially generate PKM1
protein by inclusion of exon 9 during mRNA splicing, we quanti-
fied PKM1 mRNA levels by qPCR. Some Pkm2D/D tumors had
low PKM1 expression at levels similar to Pkm2+/+ tumors,
whereas others had PKM1 mRNA levels approaching those
found in the brain, a tissue that normally expresses PKM1 (Fig-
ure 2D). To determine whether Pkm2D/D tumors had compensa-
tory expression of the other two pyruvate kinase isoforms, PKL
or PKR, we examined tumor PKLR mRNA levels by qPCR. We
did not observe any mRNA expression from the Pklr gene in
tumors of any genotype, suggesting that protein derived from
the Pkm gene was the only pyruvate kinase present (Figure 2E).
PKM2 Deletion Results in Production of Either PKM1
or a Mis-Spliced mRNA
We further characterized PKM mRNA splicing in tumors from
Pkm2+/+ and Pkm2fl/fl mice. Exons 9 and 10 are of identical
length but contain unique restriction enzyme sites that allow
for relative quantification of PKM1 and PKM2 transcript levels
(Clower et al., 2010; David et al., 2010). The alternatively spliced
region between PKM exons 8 and 11 was amplified from
Pkm2+/+ andPkm2D/D tumor cDNA andwas digested for analysis
(Figures S2C and S2E). Consistent with the qPCR results, PKM2
was the dominant transcript found in Pkm2+/+ tumors (Figure 2F).
Pkm2D/D tumors displayed an overall decrease in PKM2 mRNA,
with PKM1 message comprising a larger fraction of the total
Pkm-derived mRNAs (Figure 2G); however, this analysis also
revealed an additional PKM splice variant not found in wild-
type tumors (compare left lanes of Figures 2F and 2G). This
mRNA species accounted for 40% of the PKM transcript in
Pkm2D/D tumors (Figure 2H), was identified by sequencing to
result from the splicing of exon 8 to exon 11 (Figures S2D,
S2F, S2G), and is hereafter referred to as PKM-skip.
Splicing of PKM pre-mRNA to produce PKM2 transcript
involves repression of exon 9 inclusion and activation of exon
10 inclusion by the binding of specific splicing factors to se-
quences within the alternatively spliced exons (Clower et al.,
2010; David et al., 2010; Wang et al., 2012). Thus, the absence
of exon 10 together with repression of exon 9 likely explains
the presence of the PKM-skip mRNA species in Pkm2D/D tumors
(Chen et al., 2012). Splicing of PKM exon 8 to 11 causes a frame-
shift at the exon 8–11 junction, which results in 38 missense
codons and a premature stop codon >500 base pairs upstream
of the exon 11–12 junction (Figure S2G). Aberrant splicing of
PKM transcript to create a premature stop codon upstream of
the exon 11–12 junction leads to message degradation by
nonsense-mediated decay (Chen et al., 2012).
PKM2 Deletion Results in Variable PKM1 Protein
Levels but No PKM-skip Protein
Because deletion of Pkm2 exon 10 does not always lead to
exon 9 inclusion and production of PKM1 mRNA and because
PKM1mRNA levels varied widely across tumors, we determined
the effects of Pkm2 deletion on pyruvate kinase protein levels
in Pkm2D/D tumors. Western blotting of tumor lysates confirmedthe loss of PKM2 protein in Pkm2D/D tumors (Figure 3A). Variable
amounts of PKM1 protein were observed in Pkm2D/D tumor ly-
sates, and overall expression of pyruvate kinase was decreased
in Pkm2D/D tumors relative to Pkm2+/+ tumors, such that even
tumors with the highest PKM1 expression had lower levels
than PKM1-expressing skeletal muscle.
We next determined whether the PKM-skip mRNA generates
a protein product in Pkm2D/D tumors. Wild-type PKM1 and
PKM2 are both 531 residues long with subunit masses of 58
kD, whereas the predicted PKM-skip protein is 418 residues
long with a predicted mass of 45 kD (Figure S3A). To verify that
we could detect PKM-skip protein via western blot, PKM-skip
cDNA was expressed in E. coli with an N-terminal 63-His tag
and was purified using affinity chromatography. The same
approach is used to produce PKM2 protein that is active both
as a glycolytic enzyme (Anastasiou et al., 2012; Dombrauckas
et al., 2005) and as a putative protein kinase (Gao et al., 2012;
Yang et al., 2012a). Some PKM-skip product was recovered
from the soluble fraction after bacterial lysis; however, the ex-
pected protein was accompanied by a series of smaller pro-
ducts, consistent with partial degradation of an unstable protein
in E. coli (Figure S3B). Both the full-length and smaller polypep-
tides were recognized by two different anti-PKM antibodies
during western blot analysis (Figure S3C). We next performed
western blot analysis of tumor lysates using recombinant
PKM-skip protein as a control; however, we failed to detect a
band smaller than the full-length protein in any tumors (Fig-
ure 3B). These data show that PKM-skip protein is not present
in appreciable quantities in Pkm2D/D tumors.
Because small amounts of catalytic activity are potentially
meaningful, we considered that levels of putative PKM-skip
below our detection limit might retain some PKM2 activity. By
comparison with published PKM2 protein structures (Christofk
et al., 2008b; Dombrauckas et al., 2005), PKM-skip protein is
predicted to lack the FBP binding site and the dimer-dimer inter-
face found in the native PKM2 tetramer (Figure S3D). However,
with a few amino acid changes, the predicted PKM-skip mono-
mer retains the primary structure necessary to produce the
domains hosting the active site (Figure S3E). We thus evaluated
whether recombinant PKM-skip retained catalytic activity and
whether this protein could form dimers or tetramers. Using size
exclusion chromatography, we found that recombinant PKM-
skip eluted at volumes consistent with it being a population of
45 kD or smaller monomers (Figure S3F). PKM-skip protein
was >230,000-fold less active per microgram than recombinant
PKM2 for glycolytic pyruvate kinase activity (Figure S3G) and
had no detectable protein kinase activity (Figure S3H), suggest-
ing that PKM-skip protein would not have meaningful catalytic
activity even if it were present in Pkm2D/D tumors. Taken
together, these data suggest that PKM-skip protein is not a
confounding factor in the analysis of Pkm2D/D tumors and that
PKM exon 10 deletion effectively precludes PKM2 protein pro-
duction while still allowing cells to express PKM1.
Expression of PKM1 in PKM2 Knockout Tumors
Is Spatially Heterogeneous
To understand which cells in Pkm2D/D tumors express PKM1,
we performed immunohistochemistry (IHC) on fixed tumorCell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 401
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Figure 3. PkmExon 10Deletion inMammary
Tumors Leads to Variable Expression of
PKM Protein
(A) PKM2, PKM1, and total PKM protein levels in
Pkm2+/+ and Pkm2D/D tumors. Muscle and 293T
cell lysates serve as PKM1 and PKM2 protein
controls, respectively, with GAPDH as loading
control.
(B) PKM protein in Pkm2+/+ and Pkm2D/D tumors
visualized using a monoclonal anti-PKM antibody
with an epitope common to PKM1 and PKM2.
Muscle and 293T cell lysates serve as PKM1 and
PKM2 protein controls, respectively. The size of
full-length PKM-skip is marked with an arrowhead,
and PKM-skip degradation products are marked
with asterisks. This blot was intentionally over-
exposed.
(C) Histology and staining of one Pkm2+/+ tumor
and three Pkm2D/D tumors for PKM2 or PKM1.
Scale bars, 200 mm.
(D) High-power micrographs of the same tumors
as in (C). Scale bars, 20 mm.
See also Figure S3.sections. Consistent with previous reports (Christofk et al.,
2008a; Mazurek, 2011), most cells in Pkm2+/+ tumors stained
for PKM2, but not for PKM1 (Figures 3C and 3D). Pkm2D/D
tumors showed PKM2 staining only in adipose or other stromal
tissue associated with the tumor, with no PKM2 staining in
tumor cells. PKM1 staining was variable and was not observed
in every tumor cell in Pkm2D/D tumors (Figures 3C and 3D). Taken
together, these data suggest that PKM2 is not required by
all tumor cells and that there is a differential requirement for
pyruvate kinase among different tumor cell populations.
Generation of Tumor Cell Lines Selects
for PKM2 Expression
To further characterize Pkm2D/D tumor cells, we derived cell
lines from mammary tumors arising in Pkm2+/+ and Pkm2fl/fl
Brcafl/fl MMTV-Cre Trp53+/ mice. Generation of cell lines from
Pkm2D/D tumors took several weeks, and in all cases, the cell402 Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc.lines showed high levels of PKM2 pro-
tein expression despite the deletion of
PKM2 observed in the parental tumors
(Figure 4A). PCR genotyping of the cell
lines showed retention of at least one
Pkm2fl allele in all cases (Figure 4B),
suggesting that the transition to tissue
culture selected for rare tumor cells
that had not undergone recombination
at both Pkm loci. In sharp contrast to the
tumors from which they were derived,
the tumor cell lines showed increased
PKM2 mRNA levels (Figures 4C and 4D)
and a reduction in PKM-skip transcript
(Figure 4D).
Introduction of inducible Cre-recombi-
nase (Cre-ERT2) into two tumor cell lines
allowed for deletion of the remainingPkm2fl allele in vitro (Figure S4A), and we found that PKM2 loss
did not affect the rate of oxygen consumption in these cells or
cause dependence on b-oxidation (Figure S4B). We also investi-
gated whether nonglycolytic functions of PKM2 were active in
these cells. PKM2 was not required for hypoxia- or b-catenin-
induced gene expression (Figures S4C–S4J), suggesting that
maintenance of those functions was not the basis for the
outgrowth of rare PKM2-expressing cells during cell line
establishment. Thus, despite selection for PKM2 during cell
line generation, a functional PKM2 allele was not required for
in vitro proliferation.
Selection against PKM1 Expression, but Not for PKM2
Expression, in Allograft Tumors
Given that tissue culture conditions appear to select for PKM2-
expressing cells, we focused on in vivo analysis of Pkm2D/D
tumor-derived cell lines to examine the consequences of
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Figure 4. Cell Lines Derived from Pkm2D/D
Mammary Tumors Retain Expression of
PKM2
(A) PKM2, PKM1, and total PKM protein levels in
tumors (T) from Pkm2+/+ and Pkm2fl/fl mice and
their derivative cell lines (C). Muscle and 293T cell
lysates serve as PKM1 and PKM2 protein controls,
respectively, with GAPDH as loading control.
(B) PCR genotyping of tumors (T) from Pkm2+/+
and Pkm2fl/fl mice and their derivative cell lines (C).
Analysis of tail DNA from Pkm2+/+ and Pkm2fl/fl
mice is shown as control.
(C) PKM2 mRNA levels in Pkm2D/D tumors and
derivative cell lines by quantitative RT-PCR. Data
are shown as means ± SEM. n = 4 tumors, n = 3
cell lines.
(D) Quantification of PKM splicing in Pkm2D/D
tumor-derived cell lines and parent tumors deter-
mined as shown in Figure 2G. Data are displayed
as means ± SEM. n = 4 tumors, n = 4 cell lines.
p values were obtained by Student’s t test.
See also Figure S4.constitutive PKM1 or PKM2 expression on tumor growth in the
absence of endogenous PKM2. A representative cell line was
stably infected with Cre-ERT2 and no cDNA (empty vector con-
trol), FLAG-PKM1, or FLAG-PKM2. The presence of a FLAG-
epitope tag does not impair the ability of exogenously expressed
PKM2 to rescue any known function of the protein (Christofk
et al., 2008a, 2008b; Yang et al., 2011). The cells were treated
to delete the remaining Pkm2fl allele and were injected subcuta-
neously into nude mice. Whereas the control cells and the cells
expressing FLAG-PKM2 were competent to form tumors, the
cells expressing FLAG-PKM1 were not (Figure 5A). IHC using
an anti-FLAG antibody showed that the FLAG-PKM1-expressing
cells were detectable upon injection site biopsy 34 days later
(Figure 5B). This suggests that constitutive PKM1 expression
did not result in decreased viability but instead promoted a
state not conducive to proliferation. Interestingly, tumors derived
from FLAG-PKM2-expressing cells showed heterogeneous
FLAG staining, with only a minority of cells staining positive
(Figure 5B), and most cancer cells in these tumors did not stain
for PKM2 (Figure 5C). These data suggest that there was no
selective pressure to retain FLAG-PKM2 expression despite
deletion of the endogenous gene and confirm that constitutive,
exogenous PKM1 expression suppresses proliferation.
PKM1 Expression Is Found Only in Nonproliferating
Tumor Cells
PKM1 staining of Pkm2D/D allograft tumors showed that PKM1
is endogenously expressed in only a subpopulation of the
tumor cells (Figure 6A). Because PKM1 expression suppresses
tumor growth and decreased PKM2 activity is associated with
proproliferative signaling events and anabolic metabolism
(Anastasiou et al., 2012; Christofk et al., 2008a; Varghese
et al., 2010), we reasoned that proliferating tumor cells might
be included in the subset of cells that do not express PKM1.
Sections of Pkm2D/D allograft tumors were dual stained for
PKM1 and the proliferative marker PCNA. Areas of high PKM1staining had few proliferating cells, whereas areas of little to no
PKM1 staining had many proliferating cells (Figures 6A and
S5A). Quantification of this phenotype revealed that 26% of
cells counted stained positive for PCNA, and of the 614 PCNA-
positive cells counted, the majority (419) had low or no PKM1
staining.
To confirm that PKM1 expression is also associated with the
nonproliferating tumor cells in endogenous tumors, we dual
stained tumors from Pkm2fl/fl Brcafl/fl MMTV-Cre Trp53+/ mice
for PKM1 and PCNA. We again saw a correlation between low
PKM1 expression and staining with PCNA (Figures 6B and
S5B). In these tumors, PCNA-positive cells made up 21% of
the cells counted, and 85% of PCNA-positive cells had low to
no PKM1 expression. Dual PKM2, PCNA staining of tumors
from Pkm2fl/fl Brcafl/fl MMTV-Cre Trp53+/ mice confirmed that
cells stained positive for PCNA despite a lack of PKM2 expres-
sion (Figure 6C), supporting the notion that Pkm2D/D tumor cells
are capable of proliferation.
Variable PKM1 Expression Allows Normal Glucose
Metabolism in PKM2 Null Tumors
Our observation of low PKM1 expression in Pkm2D/D tumor cells
raises the possibility that glycolysis is disrupted in Pkm2D/D
tumors. We therefore sought to determine whether PKM2 loss
resulted in gross metabolic perturbations that would be detect-
able as changes in glycogen or lipid storage. Spontaneous
Pkm2+/+ and Pkm2D/D tumors exhibited similar periodic acid-
Schiff staining with and without diastase pretreatment, con-
sistent with tumors of both genotypes having similar glycogen
content (Figure S5C). Oil red O staining of neutral lipid stores
was also comparable between Pkm2+/+ and Pkm2D/D tumors,
with most tumors showing very little lipid accumulation in areas
devoid of fat cells (Figure S5D).
Lactate production has been associated with PKM2 expres-
sion (Christofk et al., 2008a). To investigate the effect of PKM2
deletion on tumor glucose metabolism, we determined whetherCell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 403
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Figure 5. Allograft Tumor Growth Does Not Select for PKM2 Expression
(A) Growth curves of tumors formed by Pkm2D/D cells expressing empty vector, FLAG-PKM1, or FLAG-PKM2 following injection into nude mice.
(B) Representative anti-FLAG and hematoxylin and eosin (H&E) staining of tumor sections from the allograft experiment shown in (A). Scale bars, 200 mm and
20 mm at low and high magnification, respectively.
(C) Anti-PKM2 and H&E staining of a representative Pkm2D/D empty vector tumor and three Pkm2D/D FLAG-PKM2 tumors. The upper-right Pkm2D/D FLAG-PKM2
tumor is the same Pkm2D/D FLAG-PKM2 tumor shown in (B). Scale bars, 200 mm and 20 mm at low and high magnification, respectively.
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Figure 6. Tumor Cells Proliferate in the Absence of PKM2, but Not in the Presence of PKM1
(A) Pkm2D/D allograft tumors dual stained for PKM1 (brown) and PCNA (red). Scale bars, 200 mm and 20 mm at low and high magnification, respectively.
(B) Pkm2D/D tumors from Brcafl/fl MMTV-Cre Trp53+/ mice dual stained for PKM1 (brown) and PCNA (red). Scale bars, 200 mm and 20 mm at low and high
magnification, respectively.
(C) Pkm2D/D tumors from Brcafl/fl MMTV-Cre Trp53+/ mice dual stained for PKM2 (brown) and PCNA (red). Scale bars, 20 mm.
(D) The percent lactate derived from glucose in Pkm2fl/D and Pkm2D/D allograft tumors was determined from 13C-lactate labeling in tumors normalized to 13C-
glucose serum enrichment levels. Results from two independent tumor cell line allografts are displayed asmeans ±SEM. n = 8 for line 1 tumors of both genotypes,
n = 4 for line 2 Pkm2fl/D tumors, and n = 5 for line 2 Pkm2D/D tumors.
See also Figure S5.Pkm2D/D tumors were impaired in glucose-to-lactate conversion.
Conscious mice harboring Pkm2fl/D or Pkm2D/D allograft tumors
were intravenously infused with fully labeled 13C-glucose to
achieve stable steady-state enrichment of labeled glucose in
the serum (Ayala et al., 2010; Figure S5E). Levels of labeled
lactate derived from glucose, as well as the absolute concentra-
tion of lactate, were similar in both PKM2-expressing and
PKM2 null tumors (Figures 6D and S5F). The relative abundance
of fully labeled lactate in tumors was greater than that found
in serum regardless of Pkm2 genotype, providing additional
support that the tumors produce similar amounts of lactate
from glucose (Figure S5G). These data are consistent with
heterogeneous PKM1 expression allowing populations of
Pkm2D/D tumor cells to recapitulate the metabolism found in
PKM2-expressing tumors.
Human Cancers Have PKM2 Mutations and Variable
PKM2 Expression
Given the dispensability of PKM2 for tumor growth and the
variability in pyruvate kinase expression observed in our
mouse model, we sought to determine whether variable PKM2expression might be found in primary human tumors. We
performed PKM2 and PKM1 IHC on two sets of breast tumor
tissue arrays containing a total of 317 cores (Figures 7A and
7B). PKM2 staining intensity scores revealed that, although
71% of the scored tumors show expression of PKM2, the major-
ity of these had weak PKM2 staining (score 1). Moreover, a
sizable fraction of the tumors was completely negative for
PKM2 staining (score 0), suggesting that PKM2 expression is
not consistently upregulated in human tumors (Figure 7C). An
absolute requirement for high or low PKM2 expression was not
found in any breast cancer subtype, although the more aggres-
sive HER2-positive and triple-negative breast tumor subtypes
contained the highest percentage of PKM2 negative (score 0)
tumors (Figure 7D). We found a statistically significant difference
in the distribution of PKM2 IHC scores between HER2-amplified
tumors and tumors that were ER/PR positive (p = 0.038, chi-
square test).
Because we observed acceleration of tumor-related mortality
in our mice due to PKM2 loss, we wondered whether genetic
loss or inactivation of PKM2 might also occur in some human
cancers. Sequencing of human endometrial tumor samplesCell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 405
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Figure 7. Human Breast Tumors Show Variable Expression of PKM2
(A) Representative TMA cores containing normal human breast stained with H&E and for PKM2 and PKM1. Insets show higher magnification. Scale bars, 200 mm
and 20 mm at low and high magnification, respectively.
(B) Representative TMA cores containing human breast tumor samples stained with H&E and for PKM2 and PKM1. An example of each PKM2 IHC intensity score
is shown (0, negative; 1, weak; 2, strong). Insets show higher magnification. Scale bars, 200 mm and 20 mm at low and high magnification, respectively.
(C) Distribution of PKM2 IHC intensity scores of 317 tumors from two different TMAs containing breast tumor samples.
(D) Quantification of PKM2 expression in human breast tumors relative to breast tumor subtype (triple negative, HER2 amplified, or ER/PR positive). The
distribution of PKM2 scores is significantly different between HER2-amplified samples and ER/PR-positive samples by chi-square test (p = 0.038).
(E) Schematic showing truncations of PKM2 caused by mutations found in human cancers.revealed the presence of a recurrent heterozygous nonsense
mutation (L394*) within exon 10 of PKM2 (Figure 7E). If trans-
lated, this message would result in a nonfunctional protein prod-
uct similar to PKM-skip, arguing that this is a loss-of-function
mutation.
Analysis of large-scale efforts to sequence human tumor tis-
sue via The Cancer Genome Atlas (TCGA) revealed additional
PKM2 mutations in seven cancer types (Table S1). These muta-
tions include two additional nonsense mutations (E154* and
E304*) that can only generate truncated proteins smaller than
PKM-skip (Figure 7E) and one frameshift mutation at V375 that
results in a premature stop codon. These mutations all occur
upstream of the PKM isoform-specific exons (Figure 7E and
Table S1) and are expected to result in nonsense-mediated
decay of the transcripts (Maquat, 2004) and render any protein
product nonfunctional. The remaining mutations are missense
mutations that are predicted to lower enzyme activity. These
data are consistent with selection for loss of PKM2 activity under
some situations in human cancer.406 Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc.DISCUSSION
Breast tumors in Brcafl/fl MMTV-Cre Trp53+/ mice progressed
faster despite Pkm2 deletion, and proliferation within Pkm2D/D
tumorswas associated with lowPKM1 expression. These results
are in alignment with the known regulation of PKM2 activity in
tumor cells, whereby PKM2 can exist in an active state like
that of PKM1 or in an inactive state that is promoted by signaling
events that drive cell proliferation (Christofk et al., 2008b; Lv
et al., 2011; Mazurek, 2011). Following Pkm exon 10 deletion,
the tumor cells can create analogous states of high and low
pyruvate kinase activity by titrating expression of the constitu-
tively active PKM1 isoform. Thus, the low pyruvate kinase
activity state normally induced by growth signaling can still be
maintained after PKM2 deletion by repression of exon 9 during
splicing to preclude PKM1 expression.
Regulation of PKM2 activity may act as an adaptive response
to different cellular metabolic needs, suggesting that increased
pyruvate kinase activity is important during different phases of
tumor formation and progression. Tumor initiation, either at a
primary or metastatic site, involves the ability to grow in a new,
inappropriate tissue context. An inadequate blood supply or
lack of exogenous growth and survival signals are both possible
sources of nutrient stress that might limit the proliferation and
survival of individual cancer cells (Vander Heiden et al., 2001;
Vaupel et al., 1989). Survival during these periods of stress
requires a metabolic program geared away from anabolic meta-
bolism and toward efficient ATP production, which may explain
why nonproliferating tumor cells need high pyruvate kinase
activity. The ability to activate PKM2 when proliferation is not
favored likely drives retention of PKM2 expression in cancer
and may explain why loss-of-function mutations observed in
human cancers are heterozygous. In this case, a reduction of
pyruvate kinase activity in the cell due to mutation is beneficial
for proliferative metabolism, but retention of one functional
PKM allele provides metabolic flexibility to survive periods of
stress experienced by cancer cells in vivo.
The PKMmissense mutations found in multiple human cancer
types are noteworthy because PKM2 activity is sensitive to
amino acid substitution. A functional characterization of 17 mu-
tations in PKM2 caused by rare SNPs in the human population
showed that missense mutations, even in solvent exposed
residues, resulted in reduced enzyme activity and stability
and in some cases altered the allosteric regulation of PKM2
(Allali-Hassani et al., 2009). Furthermore, our evaluation of a
large panel of breast tumors demonstrated that PKM2 protein
levels are low in many of these cancers. Because PKM2 muta-
tions have not been found at high frequencies, the observed
lower expression in some tumors may be due to decreased
transcription or translation or may be the result of epigenetic
silencing.
Apart from its role as a glycolytic enzyme, multiple nonmeta-
bolic functions that are specific to PKM2 have been implicated
in cancer, suggesting that these noncanonical activities may
drive selection for PKM2 expression in tumor cells. The fact
that cells are able to form spontaneous tumors and proliferate
after PKM2 deletion implies that nonmetabolic functions of the
PKM2 isoform are not absolutely necessary for proliferation or
tumor progression. Although recent reports have suggested
that PKM2-dependent phosphorylation of histone H3 is required
for cyclin D1 expression and progression through the cell cycle
(Yang et al., 2012a), our results indicate that this mechanism is
not absolutely required for cell-cycle control and is dispensable
for cell proliferation in at least some tumors. Other nonmetabolic
functions of PKM2 that promote gene expression through
interactions with HIF1 (Luo et al., 2011) or b-catenin (Yang
et al., 2011) or by phosphorylation of the stat3 transcription
factor (Gao et al., 2012) may occur in and be advantageous
for populations of tumor cells but are not required for growth
of all tumors.
The ability of tumor cells to proliferate without PKM2 raises
the question of whether cells with PKM2 loss and no apparent
PKM1 expression require any pyruvate kinase. It is possible
that very low levels of PKM1 expression provide sufficient pyru-
vate kinase activity to maintain glycolytic flux, which accounts
for the continued conversion of glucose to lactate in Pkm2D/D
tumors. If so, then pyruvate kinase in cancer cells must be inexcess of what is needed to allow sufficient PEP-to-pyruvate
conversion, and pyruvate kinase activity would thus never be
rate limiting at normal expression levels. However, this possibility
is not consistent with the observation that both PKM1 expres-
sion and pyruvate kinase activators can suppress tumor growth
by increasing pyruvate kinase activity (Anastasiou et al., 2012). If
the level of pyruvate kinase activity is rate limiting in proliferating
cells, then the observed loss of PKM2 without compensatory
expression of other isoforms suggests that a pyruvate-kinase-
independent mechanism for conversion of PEP to pyruvate
might exist to allow glycolytic flux to continue in the absence
of pyruvate kinase. The presence of such an activity has been
suggested and may allow cells to decouple glycolytic ATP
generation from incorporation of glucose into central metabolic
pathways (Vander Heiden et al., 2010).
The ability of Pkm2D/D tumors to convert glucose to lactate
despite negligible pyruvate kinase expression in many cells
has another possible explanation. It may be that tumor lactate
production is restricted to nonproliferating cells with high pyru-
vate kinase activity, whereas cells with low pyruvate kinase
activity consume another substrate. A similar metabolic sym-
biosis has been suggested to support cells in hypoxic regions
of tumors (Sonveaux et al., 2008).
A differential requirement for pyruvate kinase activity among
tumor cell populations complicates the development of strate-
gies to target PKM2 for cancer therapy. Although PKM2 knock-
down inhibits growth in vitro, the same does not hold true in vivo,
as inducible knockdown of PKM2 has no effect on established
xenograft tumors (Corte´s-Cros et al., 2013). That finding,
together with our observation of accelerated tumor mortality
after PKM2 deletion, suggests that pharmacological inhibition
or therapeutic knockdown of PKM2 may not be effective stand-
alone cancer therapies. Increasing pyruvate kinase activity in the
cell with small molecule activators can inhibit tumor growth
(Anastasiou et al., 2012; Parnell et al., 2013); however, our finding
that PKM1-expressing cancer cells persist in a nonproliferative
state in vivo raises the possibility that increased pyruvate kinase
activity favors survival of cancer cells under some conditions.
Additionally, pharmacological activation of PKM2 activity may
have no effect on the nonproliferating tumor cell population
and may be at best a cytostatic therapy. Finally, as at least
some tumors can tolerate loss of PKM2, the deletion, mutation,
or epigenetic silencing of PKM2 may provide a mechanism for
resistance to PKM2 activators in a therapeutic setting. Activation
or inhibition of pyruvate kinase as an adjuvant therapy may still
be effective in situations in which targeting PKM2 opposes the
biological regulation of PKM2 activity. For example, effective
PKM2 inhibition might disrupt the metabolism of the nonprolifer-
ating tumor fraction and may cause cell death or sensitize the
cells to cytotoxic therapy. The findings of this study highlight
the importance of understanding the context-dependent meta-
bolic needs of cancer cells to effectively target metabolism for
therapeutic benefit.EXPERIMENTAL PROCEDURES
Detailed descriptions of methods are provided in the Extended Experimental
Procedures.Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 407
Generation of PKM2 Conditional Mice and Embryonic Fibroblasts
PKM2 conditional mice and embryonic fibroblasts were generated using
standard protocols.
Southern Blotting, PCR Genotyping, qPCR, and Splicing Analysis
Asp718 (Roche)-digested genomic DNA was analyzed by Southern blot using
standard protocols with probe binding visualized by autoradiography. Mouse
genotypes were determined by PCR. qPCR reactions were performed using
Fast SYBRGreenMasterMix (Applied Biosystems) and PKMsplicing analyzed
as reported previously (Clower et al., 2010).
Western Blot and IHC
Western blots were performed using primary antibodies against PKM1 (Sigma
SAB4200094), PKM2 (Cell Signaling Technology #4053), PKM (Cell Signaling
Technology #3190; abcam ab6191), FLAG (Cell Signaling Technology
#2368), b-actin (abcam ab1801), or GAPDH (Cell Signaling Technology
#2118). Fixed sections were stained with the following primary antibodies
after antigen retrieval: PKM1 (Cell Signaling Technology #7067), PKM2
(Cell Signaling Technology #4053), PCNA (Cell Signaling Technology #2586),
Ki-67 (BD PharMingen 556003), cleaved caspase 3 (Cell Signaling Technology
#9661), and/or FLAG (Cell Signaling Technology #2368). PKM1/PCNA dual
staining was quantified by scoring cells as PCNA positive or negative and
PKM1 high or low/none.
Tumor Cell Lines
Trypsin-disaggregated tumor cells were propagated in DMEM with 10%
fetal bovine serum, 2 mM glutamine, and penicillin/streptomycin. Cell lines
were retrovirally infected with an MSCV-CreERT2-puro vector and pLHCX
expression vectors and were selected with puromycin and hygromycin as
described previously (Christofk et al., 2008a). 1 mM 4-hydroxytamoxifen was
used to induce recombination where indicated.
Allograft Tumor Experiments
53 106 cells were injected subcutaneously into nudemice. Tumor growth was
monitored by caliper measurement in two dimensions with volumes estimated
using the equation V = (p/6) (L*W2).
Tissue Microarray Analysis
PKM2 and PKM1 expression in human breast cancers was analyzed in three
tissue microarrays: US BioMax BR1504, one multitissue TMA-containing
tissue from the archives of the Institute of Pathology at the University of
Basel (Baumhoer et al., 2008; Schraml et al., 1999), and two breast cancer
TMAs from Beth Israel Deaconess Medical Center. Each TMA core was
independently scored for PKM2 IHC intensity. PKM2 scores from US BioMax
BR1504 were quantified relative to tumor subtype.
Human Tumor DNA Sequence Analysis
Whole-exome sequencing of 13 endometrioid endometrial tumors demon-
strated a stop codon in exon 10 of PKM (Liang et al., 2012). The PKM2
mutation was confirmed by Sequenom mass spectrometry of 234 human
endometrial cancers. Additional mutations in PKM were identified through
the cBIO portal (Cerami et al., 2012).
Mouse Glucose Infusion Studies
Catheters were implanted into the jugular vein of animals with allograft tumors
5–7 days before performing basal glucose turnover experiments, as reported
previously (Ayala et al., 2010; Jurczak et al., 2012). Conscious overnight
fasted mice were infused with U-13C-glucose for 120 min to achieve steady-
state enrichments without perturbing endogenous glucose homeostasis prior
to tissue analysis.
Mass Spectrometry Metabolite Measurement
Metabolites were prepared for analysis with isotope-labeled internal stan-
dards. The line 1 samples were analyzed as described previously (Jain et al.,
2012). In brief, metabolites were separated using a Shimatzu Prominince
UHPLC, and lactate isotopologs were measured in negative ion mode using
an ABSCIEX 5500 QTRAP equipped with a SelexION. GC-MS metabolite408 Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc.analysis employed an Agilent 7890A GC and an Agilent 5975C MS with
MIDs determined as described previously (Commisso et al., 2013). The line
2 samples were analyzed by hydrophilic interaction liquid chromatography
(HILIC)/negative ion mode MS using an Open Accela 1250 U-HPLC and a
Q Exactive hybrid quadrupole orbitrap mass spectrometer (Thermo Fisher
Scientific; Waltham, MA).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and one table and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.09.025.
ACKNOWLEDGMENTS
We thank Chu-Xia Deng for sharing the BRCA1 mouse model; Luigi Terrac-
ciano and Luigi Tornillo for providing the multitissue TMA; and Cynthia Clower,
Sarah-Maria Fendt, Andrea J. Howell, Vivian M. Liu, Sophia Lunt, Katherine R.
Mattaini, Benjamin A. Olenchock, and Kerry Pierce for technical assistance.
Eric L. Bell provided advice and reagents. Denise G. Crowley, Michael Brown,
and Kathleen S. Cormier assisted with histology. This work was supported,
in part, by NIH grants R01CA168653, 5P01CA117969, P30CA147882,
5P30CA14051, 5K08CA136983, DK059635, R01DK092606, R00CA131472,
and R01GM056203 and ADA grant 7-12-BS-09. R.A.D. and J.W.H. acknowl-
edge support from the Belfer Foundation. M.G.V.H. acknowledges additional
support from the Smith Family Foundation, the BurroughsWellcome Fund, the
Damon Runyon Cancer Research Foundation, and the Stern family. C.B.C. is a
shareholder in Agios Pharmaceuticals. M.G.V.H. is a shareholder and
Scientific Advisory Board member at Agios Pharmaceuticals. L.C.C. owns
equity in and receives compensation from Agios Pharmaceuticals and serves
on the Board of Directors and Scientific Advisory Board.
Received: February 2, 2013
Revised: July 15, 2013
Accepted: September 11, 2013
Published: October 10, 2013
REFERENCES
Allali-Hassani, A., Wasney, G.A., Chau, I., Hong, B.S., Senisterra, G., Loppnau,
P., Shi, Z., Moult, J., Edwards, A.M., Arrowsmith, C.H., et al. (2009). A survey
of proteins encoded by non-synonymous single nucleotide polymorphisms
reveals a significant fraction with altered stability and activity. Biochem. J.
424, 15–26.
Anastasiou, D., Poulogiannis, G., Asara, J.M., Boxer, M.B., Jiang, J.K., Shen,
M., Bellinger, G., Sasaki, A.T., Locasale, J.W., Auld, D.S., et al. (2011). Inhibi-
tion of pyruvate kinase M2 by reactive oxygen species contributes to cellular
antioxidant responses. Science 334, 1278–1283.
Anastasiou, D., Yu, Y., Israelsen, W.J., Jiang, J.K., Boxer, M.B., Hong, B.S.,
Tempel, W., Dimov, S., Shen, M., Jha, A., et al. (2012). Pyruvate kinase M2
activators promote tetramer formation and suppress tumorigenesis. Nat.
Chem. Biol. 8, 839–847.
Ayala, J.E., Samuel, V.T., Morton, G.J., Obici, S., Croniger, C.M., Shulman,
G.I., Wasserman, D.H., and McGuinness, O.P.; NIH Mouse Metabolic
Phenotyping Center Consortium. (2010). Standard operating procedures for
describing and performing metabolic tests of glucose homeostasis in mice.
Dis. Model. Mech. 3, 525–534.
Baumhoer, D., Tornillo, L., Stadlmann, S., Roncalli, M., Diamantis, E.K., and
Terracciano, L.M. (2008). Glypican 3 expression in human nonneoplastic,
preneoplastic, and neoplastic tissues: a tissue microarray analysis of 4,387
tissue samples. Am. J. Clin. Pathol. 129, 899–906.
Cairns, R.A., Harris, I.S., andMak, T.W. (2011). Regulation of cancer cell meta-
bolism. Nat. Rev. Cancer 11, 85–95.
Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A.,
Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBiol.
cancer genomics portal: an open platform for exploring multidimensional
cancer genomics data. Cancer Discov. 2, 401–404.
Chaneton, B., and Gottlieb, E. (2012). Rocking cell metabolism: revised func-
tions of the key glycolytic regulator PKM2 in cancer. Trends Biochem. Sci. 37,
309–316.
Chaneton, B., Hillmann, P., Zheng, L., Martin, A.C., Maddocks, O.D., Chokka-
thukalam, A., Coyle, J.E., Jankevics, A., Holding, F.P., Vousden, K.H., et al.
(2012). Serine is a natural ligand and allosteric activator of pyruvate kinase
M2. Nature 491, 458–462.
Chen, M., David, C.J., and Manley, J.L. (2012). Concentration-dependent
control of pyruvate kinase M mutually exclusive splicing by hnRNP proteins.
Nat. Struct. Mol. Biol. 19, 346–354.
Christofk, H.R., Vander Heiden, M.G., Harris, M.H., Ramanathan, A., Gerszten,
R.E.,Wei, R., Fleming,M.D., Schreiber, S.L., and Cantley, L.C. (2008a). TheM2
splice isoform of pyruvate kinase is important for cancer metabolism and
tumour growth. Nature 452, 230–233.
Christofk, H.R., Vander Heiden, M.G., Wu, N., Asara, J.M., and Cantley, L.C.
(2008b). Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature
452, 181–186.
Clower, C.V., Chatterjee, D., Wang, Z., Cantley, L.C., Vander Heiden, M.G.,
and Krainer, A.R. (2010). The alternative splicing repressors hnRNP A1/A2
and PTB influence pyruvate kinase isoform expression and cell metabolism.
Proc. Natl. Acad. Sci. USA 107, 1894–1899.
Commisso, C., Davidson, S.M., Soydaner-Azeloglu, R.G., Parker, S.J., Kam-
phorst, J.J., Hackett, S., Grabocka, E., Nofal, M., Drebin, J.A., Thompson,
C.B., et al. (2013). Macropinocytosis of protein is an amino acid supply route
in Ras-transformed cells. Nature 497, 633–637.
Corte´s-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J.S., Yin,
H., Muller, A., Haberkorn, A., Chene, P., Sellers, W.R., and Hofmann, F. (2013).
M2 isoform of pyruvate kinase is dispensable for tumor maintenance and
growth. Proc. Natl. Acad. Sci. USA 110, 489–494.
David, C.J., Chen,M., Assanah,M., Canoll, P., andManley, J.L. (2010). HnRNP
proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in
cancer. Nature 463, 364–368.
Dombrauckas, J.D., Santarsiero, B.D., and Mesecar, A.D. (2005). Structural
basis for tumor pyruvate kinase M2 allosteric regulation and catalysis.
Biochemistry 44, 9417–9429.
Gao, X., Wang, H., Yang, J.J., Liu, X., and Liu, Z.R. (2012). Pyruvate kinase
M2 regulates gene transcription by acting as a protein kinase. Mol. Cell 45,
598–609.
Goldberg, M.S., and Sharp, P.A. (2012). Pyruvate kinase M2-specific siRNA
induces apoptosis and tumor regression. J. Exp. Med. 209, 217–224.
Hitosugi, T., Kang, S., Vander Heiden, M.G., Chung, T.W., Elf, S., Lythgoe, K.,
Dong, S., Lonial, S., Wang, X., Chen, G.Z., et al. (2009). Tyrosine phosphory-
lation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci.
Signal. 2, ra73.
Imamura, K., and Tanaka, T. (1972). Multimolecular forms of pyruvate
kinase from rat and other mammalian tissues. I. Electrophoretic studies.
J. Biochem. 71, 1043–1051.
Jain, M., Nilsson, R., Sharma, S., Madhusudhan, N., Kitami, T., Souza, A.L.,
Kafri, R., Kirschner, M.W., Clish, C.B., and Mootha, V.K. (2012). Metabolite
profiling identifies a key role for glycine in rapid cancer cell proliferation.
Science 336, 1040–1044.
Jurczak, M.J., Lee, A.H., Jornayvaz, F.R., Lee, H.Y., Birkenfeld, A.L., Guigni,
B.A., Kahn, M., Samuel, V.T., Glimcher, L.H., and Shulman, G.I. (2012).
Dissociation of inositol-requiring enzyme (IRE1a)-mediated c-Jun N-terminal
kinase activation from hepatic insulin resistance in conditional X-box-binding
protein-1 (XBP1) knock-out mice. J. Biol. Chem. 287, 2558–2567.
Keller, K.E., Tan, I.S., and Lee, Y.S. (2012). SAICAR stimulates pyruvate kinase
isoform M2 and promotes cancer cell survival in glucose-limited conditions.
Science 338, 1069–1072.
Liang, H., Cheung, L.W., Li, J., Ju, Z., Yu, S., Stemke-Hale, K., Dogruluk, T., Lu,
Y., Liu, X., Gu, C., et al. (2012). Whole-exome sequencing combined withfunctional genomics reveals novel candidate driver cancer genes in endome-
trial cancer. Genome Res. 22, 2120–2129.
Luo, W., Hu, H., Chang, R., Zhong, J., Knabel, M., O’Meally, R., Cole, R.N.,
Pandey, A., and Semenza, G.L. (2011). Pyruvate kinase M2 is a PHD3-
stimulated coactivator for hypoxia-inducible factor 1. Cell 145, 732–744.
Lv, L., Li, D., Zhao, D., Lin, R., Chu, Y., Zhang, H., Zha, Z., Liu, Y., Li, Z., Xu, Y.,
et al. (2011). Acetylation targets the M2 isoform of pyruvate kinase for
degradation through chaperone-mediated autophagy and promotes tumor
growth. Mol. Cell 42, 719–730.
Maquat, L.E. (2004). Nonsense-mediated mRNA decay: splicing, translation
and mRNP dynamics. Nat. Rev. Mol. Cell Biol. 5, 89–99.
Mazurek, S. (2011). Pyruvate kinase type M2: a key regulator of the metabolic
budget system in tumor cells. Int. J. Biochem. Cell Biol. 43, 969–980.
Noguchi, T., Inoue, H., and Tanaka, T. (1986). The M1- and M2-type isozymes
of rat pyruvate kinase are produced from the same gene by alternative RNA
splicing. J. Biol. Chem. 261, 13807–13812.
Parnell, K.M., Foulks, J.M., Nix, R.N., Clifford, A., Bullough, J., Luo, B., Senina,
A., Vollmer, D., Liu, J., McCarthy, V., et al. (2013). Pharmacologic activation of
PKM2 slows lung tumor Xenograft growth. Mol. Cancer Ther. 12, 1453–1460.
Salk, J.J., Fox, E.J., and Loeb, L.A. (2010). Mutational heterogeneity in human
cancers: origin and consequences. Annu. Rev. Pathol. 5, 51–75.
Schraml, P., Kononen, J., Bubendorf, L., Moch, H., Bissig, H., Nocito, A.,
Mihatsch, M.J., Kallioniemi, O.P., and Sauter, G. (1999). Tissue microarrays
for gene amplification surveys in many different tumor types. Clin. Cancer
Res. 5, 1966–1975.
Sonveaux, P., Ve´gran, F., Schroeder, T., Wergin, M.C., Verrax, J., Rabbani,
Z.N., De Saedeleer, C.J., Kennedy, K.M., Diepart, C., Jordan, B.F., et al.
(2008). Targeting lactate-fueled respiration selectively kills hypoxic tumor cells
in mice. J. Clin. Invest. 118, 3930–3942.
Vander Heiden, M.G., Plas, D.R., Rathmell, J.C., Fox, C.J., Harris, M.H., and
Thompson, C.B. (2001). Growth factors can influence cell growth and survival
through effects on glucose metabolism. Mol. Cell. Biol. 21, 5899–5912.
Vander Heiden, M.G., Cantley, L.C., and Thompson, C.B. (2009). Understand-
ing the Warburg effect: the metabolic requirements of cell proliferation.
Science 324, 1029–1033.
Vander Heiden, M.G., Locasale, J.W., Swanson, K.D., Sharfi, H., Heffron, G.J.,
Amador-Noguez, D., Christofk, H.R., Wagner, G., Rabinowitz, J.D., Asara,
J.M., and Cantley, L.C. (2010). Evidence for an alternative glycolytic pathway
in rapidly proliferating cells. Science 329, 1492–1499.
Varghese, B., Swaminathan, G., Plotnikov, A., Tzimas, C., Yang, N., Rui, H.,
and Fuchs, S.Y. (2010). Prolactin inhibits activity of pyruvate kinase M2 to
stimulate cell proliferation. Mol. Endocrinol. 24, 2356–2365.
Vaupel, P., Kallinowski, F., and Okunieff, P. (1989). Blood flow, oxygen and
nutrient supply, and metabolic microenvironment of human tumors: a review.
Cancer Res. 49, 6449–6465.
Wang, Z., Chatterjee, D., Jeon, H.Y., Akerman, M., Vander Heiden, M.G.,
Cantley, L.C., and Krainer, A.R. (2012). Exon-centric regulation of pyruvate
kinase M alternative splicing via mutually exclusive exons. J. Mol. Cell Biol.
4, 79–87.
Xu, X., Wagner, K.U., Larson, D., Weaver, Z., Li, C., Ried, T., Hennighausen, L.,
Wynshaw-Boris, A., and Deng, C.X. (1999). Conditional mutation of Brca1 in
mammary epithelial cells results in blunted ductal morphogenesis and tumour
formation. Nat. Genet. 22, 37–43.
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K.,
and Lu, Z. (2011). Nuclear PKM2 regulates b-catenin transactivation upon
EGFR activation. Nature 480, 118–122.
Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T.,
Alfred Yung, W.K., and Lu, Z. (2012a). PKM2 phosphorylates histone H3 and
promotes gene transcription and tumorigenesis. Cell 150, 685–696.
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C.A., Aldape,
K., Cantley, L.C., and Lu, Z. (2012b). ERK1/2-dependent phosphorylation
and nuclear translocation of PKM2 promotes the Warburg effect. Nat. Cell
Biol. 14, 1295–1304.Cell 155, 397–409, October 10, 2013 ª2013 Elsevier Inc. 409
